WASHINGTON — The Casey Means nomination for U.S. surgeon general remained stuck in the Senate at the start of April, while Health Secretary Robert F. Kennedy Jr.’s Make America Healthy Again, or MAHA, agenda kept colliding with legal and operational setbacks inside the federal health apparatus. The delay matters because Means has become one of the clearest public faces of Kennedy’s chronic-disease message just as a federal vaccine ruling and a prolonged leadership vacuum at the Centers for Disease Control and Prevention are slowing the administration’s effort to turn MAHA politics into durable policy, April 4, 2026.
The Senate HELP Committee’s nominations page still lists Means’ nomination, received Jan. 13, 2026, with the last action as “Hearings held,” showing that it has not advanced since her hearing. An Associated Press report last week said the nomination had stalled as senators continued to question her experience and vaccine stance.
Why the Casey Means nomination is still stuck
At her Feb. 25 confirmation hearing, Means pitched a health agenda centered on food, chronic disease and overmedicalization, while also promising to resign from business roles if confirmed. But the hearing also revived doubts about her inactive Oregon medical license, her unfinished surgical residency and her past comments on vaccines and birth control, giving skeptics in both parties more reasons to pause.
Murkowski told reporters she was still “in the same spot” about her concerns, according to AP, a sign that the White House has not yet locked down the Republican support needed to move Means forward. That uncertainty has turned the nomination into a broader test of how much pull Kennedy’s coalition really has on Capitol Hill.
MAHA’s court and CDC hurdles are growing
The nomination is also getting squeezed by a tougher political backdrop. Reuters reported on April 1 that a federal judge had already blocked key parts of Kennedy’s vaccine overhaul and the administration still had not appealed two weeks later, including the move to sharply cut the number of broadly recommended childhood vaccinations and the removal and replacement of members of a CDC vaccine advisory committee.
At the same time, Reuters reported that the White House missed the March 25 deadline to name a permanent CDC director, leaving NIH Director Jay Bhattacharya to keep overseeing the agency through delegable duties. That prolonged vacancy has kept the CDC in a state of uncertainty and added to the administration’s challenge in showing it can quickly consolidate control over the public health agencies Kennedy wants to reshape.
Casey Means nomination fits a longer MAHA power struggle
The current standoff is easier to understand in sequence. Trump first nominated Means in May 2025, Kennedy then fired all 17 members of the CDC’s outside vaccine advisory panel in June, and the administration’s confrontation with career public health leadership deepened in August when CDC Director Susan Monarez was fired after clashing with Kennedy over vaccine policy.
Taken together, those earlier turns explain why this is no longer just a nomination fight. The Casey Means nomination has become a measure of whether MAHA can convert its messaging and political energy into confirmed leadership posts and lasting leverage inside the federal health bureaucracy.
For now, Means remains in limbo, Kennedy’s vaccine agenda is partly blocked in court, and the CDC still lacks stable Senate-confirmed leadership. Until one of those pieces moves, MAHA will keep looking more like a movement with influence than an agenda in full control of the machinery it wants to remake.
